Erik Ostrowski Biography and Net Worth

Senior Vice President, Chief Financial Officer & Chief Business Officer of Akebia Therapeutics

Erik Ostrowski joined Akebia in June 2024 as Senior Vice President, Chief Financial Officer and Chief Business Officer. He also serves as Treasurer. Prior to joining Akebia, Mr. Ostrowski was as President, Interim Chief Executive Officer, Chief Financial Officer, and Treasurer of AVROBIO, Inc., a public biotechnology company, from May 2023 to June 2024 and served as its Chief Financial Officer and Treasurer from January 2019 to May 2023. From 2014 to 2018, Mr. Ostrowski served as the Chief Financial Officer of Summit Therapeutics plc., a public biotechnology company. Prior to that, he served as Vice President of Finance at Organogenesis Inc., a biotechnology company, from July 2010 to June 2014. Mr. Ostrowski previously worked in investment banking, most recently as a director with Leerink Partners LLC. Mr. Ostrowski began his career as an accountant with Coopers & Lybrand (now PricewaterhouseCoopers). Mr. Ostrowski served on the Board of Directors of Faron Pharmaceuticals Oy, a public biopharmaceutical company, from April 2022 to April 2024. He received a B.S. in accounting and economics from Babson College and a M.B.A. from the University of Chicago Booth School of Business.

What is Erik Ostrowski's net worth?: The estimated net worth of Erik Ostrowski is at least $800.70 thousand as of June 30th, 2025. Mr. Ostrowski owns 503,586 shares of Akebia Therapeutics stock worth more than $800,702 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Ostrowski may own. Learn More about Erik Ostrowski's net worth.
How old is Erik Ostrowski?: Mr. Ostrowski is currently 52 years old. There are 4 older executives and no younger executives at Akebia Therapeutics. The oldest executive at Akebia Therapeutics is Dr. Steven Keith Burke M.D., Senior VP of Research & Development and Chief Medical Officer, who is 63 years old. Learn More on Erik Ostrowski's age.
How do I contact Erik Ostrowski?: The corporate mailing address for Mr. Ostrowski and other Akebia Therapeutics executives is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. Akebia Therapeutics can also be reached via phone at (617) 871-2098 and via email at [email protected]. Learn More on Erik Ostrowski's contact information.
Has Erik Ostrowski been buying or selling shares of Akebia Therapeutics?: Erik Ostrowski has not been actively trading shares of Akebia Therapeutics within the last three months. Most recently, Erik Ostrowski sold 41,314 shares of the business's stock in a transaction on Monday, June 30th. The shares were sold at an average price of $3.67, for a transaction totalling $151,622.38. Following the completion of the sale, the chief financial officer now directly owns 503,586 shares of the company's stock, valued at $1,848,160.62. Learn More on Erik Ostrowski's trading history.
Who are Akebia Therapeutics' active insiders?: Akebia Therapeutics' insider roster includes Steven Burke (SVP), John Butler (CEO), Violetta Cotreau (CAO), Michel Dahan (COO), Steven Gilman (Director), Nicholas Grund (Insider), Richard Malabre (CAO), Erik Ostrowski (Senior Vice President, Chief Financial Officer & Chief Business Officer), and David Spellman (CFO). Learn More on Akebia Therapeutics' active insiders.
Are insiders buying or selling shares of Akebia Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 7 times. They sold a total of 350,227 shares worth more than $848,057.30. The most recent insider tranaction occured on June, 30th when CFO Erik Ostrowski sold 41,314 shares worth more than $151,622.38. Insiders at Akebia Therapeutics own 3.0% of the company. Learn More about insider trades at Akebia Therapeutics.
Information on this page was last updated on 6/30/2025.

Erik Ostrowski Insider Trading History at Akebia Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/30/2025	Sell	41,314	$3.67	$151,622.38	503,586

Erik Ostrowski Buying and Selling Activity at Akebia Therapeutics

Akebia Therapeutics Company Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $1.59

$1.53

$1.61

50 Day Range

MA: $2.29

$1.47

$3.17

2 Week Range

Now: $1.59

$1.45

$4.08

Volume

1,995,511 shs

Average Volume

4,952,545 shs

Market Capitalization

$421.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31

Erik Ostrowski Biography and Net Worth

What is Erik Ostrowski's net worth?

How old is Erik Ostrowski?

How do I contact Erik Ostrowski?

Has Erik Ostrowski been buying or selling shares of Akebia Therapeutics?

Who are Akebia Therapeutics' active insiders?

Are insiders buying or selling shares of Akebia Therapeutics?